18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules


I'm Interested

Trial ID: NCT03824535


This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.

Official Title

18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules

Stanford Investigator(s)

Carina Mari Aparici
Carina Mari Aparici

Clinical Professor, Radiology - Rad/Nuclear Medicine


Inclusion Criteria:

   - Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be
   eligible if the dominant nodule is 7 to 30 mm

   - Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)

   - Current or former cigarette smoker, with >= 20 pack years

   - Documented informed consent

Exclusion Criteria:

   - History or previous diagnosis of lung cancer

   - Cancer diagnosis within the last 5 years

   - Pregnant or nursing


procedure: Computed Tomography

drug: Fludeoxyglucose F-18

drug: Fluorine F 18 L-glutamate Derivative BAY94-9392

procedure: Positron Emission Tomography


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mahima Goel

New Trial Alerts

Receive email alerts when trials open to patients.